AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel VSV-Based Vaccine Platform for Zika Virus

Detailed Technology Description: None

Countries: United States

Application No.: 62/584,629

*Abstract: There is currently no vaccine available for protecting against Zika virus (ZIKV) infection and disease. Researchers at Nationwide Children’s Hospital have developed multiple novel vaccine candidates using vesicular stomatitis virus (VSV) to express specific ZIKV proteins. VSV is a bovine virus that is partially attenuated in humans and has been used previously as a vaccine vector for other viruses, including a candidate vaccine for Ebola that has been successful in recent clinical trials. The protection conferred by these candidate ZIKV vaccines does not rely on antibodies against the ZIKV envelope proteins and thus eliminates concern of Antibody Dependent Enhancement or cross-reactivity with other species of flavivirus. These ZIKV candidate vaccines are highly attenuated yet induce an effective, protective immune response against ZIKV infection and disease in both a standard and a highly sensitive mouse model.

*Inquiry: Andrew CorrisThe Research Institute at Nationwide Children’s HospitalOffice of Technology Commercialization700 Children’s DriveColumbus, OH 43205T: (614) 355-1604 F: (614) 722-2716Andrew.Corris@nationwidechildrens.org

*IP Issue Date: None

*IP Type: Provisional

Country/Region: USA

For more information, please click Here